loader2
Login Open ICICI 3-in-1 Account
IPOLogoImag

ANTHEM BIOSCIENCES IPO

IPO Details

-
-
26 Shares
₹ 14,820
₹ 540 – 570
₹ Up to 3395 Cr

Issue timeline

  • -
  • 17-Jul-2025
  • 18-Jul-2025
  • 18-Jul-2025
  • 21-Jul-2025

Subscription Status

Shareholder -
Qualified Institutional Buyers -
Non-Institutional Investor -
Retail Individual Investor -
Employee -
Total -

About Company

About Anthem Biosciences

Founded in 2006 and headquartered in Bengaluru, Anthem Biosciences offers end-to-end services in drug discovery, development, and commercial manufacturing. The company specializes in fermentation-based advanced APIs and specialty ingredients such as peptides, enzymes, probiotics, biosimilars, and nutritional actives.

With two manufacturing units in Karnataka (Bommasandra and Harohalli), it currently has annual capacities of:

  • 270kL for custom synthesis
  • 142kL for fermentation

A third facility (Neoanthem Lifesciences) is under construction and is expected to raise the fermentation capacity to 182 kL by mid-FY26.

Anthem serves 550+ global clients spread across 44 countries, including the U.S., Europe, and Japan. It has also struck strategic ties—like with DavosPharma in the U.S.—to expand its biotechnology footprint.

 

IPO Details

  • IPO Dates- July 14 to July 16, 2025
  • Price Band- ₹540 – ₹570 per share
  • Issue Size- ₹3,395 crore (100% OFS)
  • Lot Size- 26 shares
  • Investor Quota- QIB 50%, Retail 35%, HNI 15%
  • Tentative Listing Date- July 21, 2025

This IPO is entirely a stake sale by promoters and existing shareholders. The company will not receive any funds from it. Funds will go directly to the selling shareholders after deducting related expenses and taxes.

 

Financial Performance

Financial Metrics

31 Mar 2025

31 Mar 2024

31 Mar 2023

Assets

2,807.58

2,398.11

2,014.46

Revenue

1,930.29

1,483.07

1,133.99

Net Worth

2,409.86

1,924.66

1,740.67

Profit After Tax

451.26

367.31

385.19

Reserves and Surplus

2,298.05

1,815.39

1,628.88

Total Borrowing

108.95

232.53

125.06

(Amount in Cr)

Financial Highlights & Trends

  • Strong Revenue Growth: The company’s revenue has grown significantly year-on-year, increasing by over 70% from FY23 to FY25.
  • Consistent Profitability: Anthem has remained profitable each year, with a 17% rise in PAT in FY25 compared to FY24.
  • Robust Net Worth: Rising net worth and reserves show the company is retaining earnings and strengthening its financial base.
  • Reduced Borrowing: A sharp reduction in total borrowing in FY25 reflects improved debt management and internal funding capacity.
  • Asset Expansion: Steady asset growth indicates investments in new facilities and business expansion.

Anthem Biosciences is financially sound with strong growth in both revenue and profits, making it an attractive IPO candidate for long-term investors.

 

Key Strengths

  1. One-Stop CRDMO Platform: Anthem offers integrated discovery, development, and manufacturing for both small molecules (NCE) and biologics (NBE)—rare in India’s CRDMO space.
  2. Global Reach: Serving over 550 customers across 44 countries, Anthem is well-integrated with global pharmaceutical value chains.
  3. Leading Fermentation Capacity: With 142 kL now expanding to 182 kL, Anthem leads domestic fermentation infrastructure—a critical differentiator in biotech APIs.
  4. Innovation-led Services: Specialties like peptides, probiotics, enzymes, GLP‑1 analogues, and biosimilars support emerging biotech firms and niche biotech demand.

 

Key Risks to Consider

  1. Total OFS Issue: As an OFS, investors get no fresh equity—market value depends entirely on secondary sale pricing and perception.
  2. Customer Concentration: Business is tilted towards CRDMO services that contributed over 81% of revenue in FY25; dependence on large pharma clients may impact stability if clients change strategy or face slowdowns.
  3. Sector Volatility: CRDMO firms face regulatory, quality, and compliance scrutiny across global markets—any misstep could impact operations.
  4. Execution Risk: Scaling fermentation capacity and new units aggressively in biotech segments can encounter implementation delays and cost overruns.

 

Who Might Consider Investing?

  • Long-Term Investors: Those bullish on India’s rising role in global pharma outsourcing and biotech innovation.
  • Healthcare & CRDMO Fans: Investors focused on segmented growth plays in niche biopharma infrastructure.
  • Institutional Players: Seeking exposure to high‐growth specialty APIs and fermentation services with robust margin profile.

 

Final Thoughts

The Anthem Biosciences IPO represents a rare opportunity to invest in India’s rising CRDMO wave. With strong growth, high margins, expanding fermentation capacity, and a global client base, the company has key ingredients for long-term relevance. However, investors need to assess valuation carefully, given the OFS structure and rising valuation ambitions. Market sentiment, execution risk in fermentation scale-up, and dependence on biotech trends must also be weighed. With pricing set between ₹540–₹570/share and a listing expected on July 21, 2025, Anthem’s IPO is one of the most anticipated healthcare IPOs of 2025. Those eyeing the biotech and pharma services sector may find this a strategic yet selective entry point.

*The financials mentioned above are sourced from DRHP/ RHP documents.